中国药物与临床
中國藥物與臨床
중국약물여림상
CHINESE REMEDIES & CLINICS
2014年
7期
873-875
,共3页
肖帅帅%程彩霞%董金%杜志杰%张燕燕%王芳%刘杰昊%郭建%刘静
肖帥帥%程綵霞%董金%杜誌傑%張燕燕%王芳%劉傑昊%郭建%劉靜
초수수%정채하%동금%두지걸%장연연%왕방%류걸호%곽건%류정
乳腺肿瘤%免疫组织化学%Mps1%p-ERK%BRafV600E
乳腺腫瘤%免疫組織化學%Mps1%p-ERK%BRafV600E
유선종류%면역조직화학%Mps1%p-ERK%BRafV600E
Breast neoplasms%Immunohistochemistry%Mps1%p-ERK%BRafV600E
目的:明确BRafV600E/ERK通路与单极纺锤体蛋白激酶1(Mps1)在乳腺癌发生发展中的相关性。方法采用免疫组织化学技术检测60例乳腺癌、20例乳腺良性疾病Mps1蛋白以及p-ERK的表达情况。结果 Mps1蛋白在乳腺癌中阳性表达率为77%(46/60)明显高于乳腺良性疾病10%(2/20)(P<0.01),p-ERK在乳腺癌中阳性表达率为83%(50/60)明显高于乳腺良性疾病33%(5/15)(P<0.01),p-ERK表达阳性的病例同时显示Mps1阳性表达,反之亦然。二者在乳腺癌中显著相关(R2=0.367,P<0.05)。且Mps1蛋白的表达与年龄无关(P>0.05),而在有淋巴结转移乳腺癌中的表达水平高于无淋巴结转移(P<0.05),在Ⅲ+Ⅳ期的表达水平高于Ⅰ+Ⅱ期(P<0.05)。结论 Mps1与BRafV600E/ERK通路在乳腺癌发生发展中呈正相关,且Mps1蛋白表达与有无淋巴结转移、TNM临床分期密切相关。
目的:明確BRafV600E/ERK通路與單極紡錘體蛋白激酶1(Mps1)在乳腺癌髮生髮展中的相關性。方法採用免疫組織化學技術檢測60例乳腺癌、20例乳腺良性疾病Mps1蛋白以及p-ERK的錶達情況。結果 Mps1蛋白在乳腺癌中暘性錶達率為77%(46/60)明顯高于乳腺良性疾病10%(2/20)(P<0.01),p-ERK在乳腺癌中暘性錶達率為83%(50/60)明顯高于乳腺良性疾病33%(5/15)(P<0.01),p-ERK錶達暘性的病例同時顯示Mps1暘性錶達,反之亦然。二者在乳腺癌中顯著相關(R2=0.367,P<0.05)。且Mps1蛋白的錶達與年齡無關(P>0.05),而在有淋巴結轉移乳腺癌中的錶達水平高于無淋巴結轉移(P<0.05),在Ⅲ+Ⅳ期的錶達水平高于Ⅰ+Ⅱ期(P<0.05)。結論 Mps1與BRafV600E/ERK通路在乳腺癌髮生髮展中呈正相關,且Mps1蛋白錶達與有無淋巴結轉移、TNM臨床分期密切相關。
목적:명학BRafV600E/ERK통로여단겁방추체단백격매1(Mps1)재유선암발생발전중적상관성。방법채용면역조직화학기술검측60례유선암、20례유선량성질병Mps1단백이급p-ERK적표체정황。결과 Mps1단백재유선암중양성표체솔위77%(46/60)명현고우유선량성질병10%(2/20)(P<0.01),p-ERK재유선암중양성표체솔위83%(50/60)명현고우유선량성질병33%(5/15)(P<0.01),p-ERK표체양성적병례동시현시Mps1양성표체,반지역연。이자재유선암중현저상관(R2=0.367,P<0.05)。차Mps1단백적표체여년령무관(P>0.05),이재유림파결전이유선암중적표체수평고우무림파결전이(P<0.05),재Ⅲ+Ⅳ기적표체수평고우Ⅰ+Ⅱ기(P<0.05)。결론 Mps1여BRafV600E/ERK통로재유선암발생발전중정정상관,차Mps1단백표체여유무림파결전이、TNM림상분기밀절상관。
Objective To determine the correlation between Mps1 and BRaf V600E/ERK pathway in breast cancer. Methods The correlation between Mps1 and p-ERK was evaluated by using immunohistochemistry in 60 patients with breast cancer and 20 with benign breast diseases. Results The positivity of Mps1 [(77% (46/60) vs.10% (2/20), P<0.01] and p-ERK [33%(5/15) vs. 83%(50/60), P<0.01] in breast cancer was significantly higher than that in breast benign diseases. The samples with p-ERK immunostaining positive also showed immunoreactivity of Mps1, and the vice versa, suggesting that Mps1 expression was positively correlated with p-ERK in breast cancer (R2=0.367, P<0.05). The level of Mps1 expression was unrelated to the age in breast cancer ( P>0.05). The level of Mps1 expression was higher in patients with lymph node metastasis than those without, and higher in phase Ⅲ+Ⅳ breast cancer than in phaseⅠ+Ⅱ breast cancer (both P<0.05). Conclusion The Mps1 correlates with the activity of BRaf V600E signaling in breast cancer and is closely associated with lymph node metastasis and clinical stage of TNM.